Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurasidone Hydrochloride

FDA-approved product (tablet, oral), marketed as Latuda, Lurasidone Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lurasidone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bipolar disorder
  • Bipolar I disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurasidone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurasidone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Major Depressive Disorder With Mixed Features - Extension

    NCT01423253 · start 2011-09

    Registered record
    Registry ID
    NCT01423253
    Conditions
    Major Depressive Disorder
    Interventions
    Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-10
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionLurasidone
    PhasePhase 3
    Registry statusCompleted

  • PEARL Schizophrenia Maintenance

    NCT01435928 · start 2011-09

    Registered record
    Registry ID
    NCT01435928
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-08
    Enrolment
    676

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; Matching Placebo
    PhasePhase 3
    Registry statusCompleted

  • Lurasidone Extended Use Study

    NCT01485640 · start 2011-06

    Registered record
    Registry ID
    NCT01485640
    Conditions
    Schizophrenia; Bipolar Disorder
    Interventions
    Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-06
    Completion
    2014-02
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Bipolar Disorder
    InterventionLurasidone
    PhasePhase 3
    Registry statusCompleted

  • A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

    NCT01143090 · start 2010-08

    Registered record
    Registry ID
    NCT01143090
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    Not recorded
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionLurasidone HCl
    PhasePhase 3
    Registry statusCompleted

  • A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

    NCT01143077 · start 2010-06

    Registered record
    Registry ID
    NCT01143077
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-05
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionLurasidone HCl
    PhasePhase 3
    Registry statusCompleted

  • Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

    NCT01074632 · start 2009-05

    Registered record
    Registry ID
    NCT01074632
    Conditions
    Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-05
    Completion
    2009-09
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
    InterventionLurasidone HCl
    PhasePhase 1
    Registry statusCompleted

  • Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

    NCT00868699 · start 2009-04

    Registered record
    Registry ID
    NCT00868699
    Conditions
    Bipolar Depression
    Interventions
    lurasidone; lurasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-02
    Enrolment
    505

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    Interventionlurasidone; lurasidone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

    NCT00868959 · start 2009-04

    Registered record
    Registry ID
    NCT00868959
    Conditions
    Bipolar Depression
    Interventions
    lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-02
    Enrolment
    817

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    Interventionlurasidone
    PhasePhase 3
    Registry statusCompleted

  • Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

    NCT00789698 · start 2008-12

    Registered record
    Registry ID
    NCT00789698
    Conditions
    Chronic Schizophrenia
    Interventions
    Lurasidone HC1; Quetiapine XR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-07
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Schizophrenia
    InterventionLurasidone HC1; Quetiapine XR
    PhasePhase 3
    Registry statusCompleted

  • A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

    NCT01979679 · start 2008-12

    Registered record
    Registry ID
    NCT01979679
    Conditions
    Schizophrenia
    Interventions
    Lurasidone 80 mg; Lurasidone 120 mg; Lurasidone 160 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    Not recorded
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone 80 mg; Lurasidone 120 mg; Lurasidone 160 mg
    PhasePhase 3
    Registry statusCompleted

  • Midazolam Drug-Drug Interaction Study With Lurasidone HCl

    NCT01082263 · start 2008-10

    Registered record
    Registry ID
    NCT01082263
    Conditions
    Schizophrenia Patients
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia Patients
    InterventionLurasidone HCl
    PhasePhase 1
    Registry statusCompleted

  • Digoxin Drug-Drug Interaction With Lurasidone HCl

    NCT01082289 · start 2008-09

    Registered record
    Registry ID
    NCT01082289
    Conditions
    Schizophrenia
    Interventions
    Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone
    PhasePhase 1
    Registry statusCompleted

  • Lithium Drug-Drug Interaction Study With Lurasidone HCl

    NCT01074073 · start 2008-08

    Registered record
    Registry ID
    NCT01074073
    Conditions
    Schizophrenia
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2008-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone HCl
    PhasePhase 1
    Registry statusCompleted

  • Rifampin Drug-Drug Interaction Study With Lurasidone HCl

    NCT01082276 · start 2008-08

    Registered record
    Registry ID
    NCT01082276
    Conditions
    Male, Healthy Normal Subjects
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2008-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale, Healthy Normal Subjects
    InterventionLurasidone HCl
    PhasePhase 1
    Registry statusCompleted

  • The Bioequivalence Of Two Different Lurasidone Formulations In Patients

    NCT01082250 · start 2008-07

    Registered record
    Registry ID
    NCT01082250
    Conditions
    Schizophrenia
    Interventions
    Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone HCl
    PhasePhase 1
    Registry statusCompleted